Literature DB >> 28993509

A Large-Scale RNAi Screen Identifies SGK1 as a Key Survival Kinase for GBM Stem Cells.

Shreya Kulkarni1, Surbhi Goel-Bhattacharya1, Sejuti Sengupta1, Brent H Cochran2.   

Abstract

Glioblastoma multiforme (GBM) is the most common type of primary malignant brain cancer and has a very poor prognosis. A subpopulation of cells known as GBM stem-like cells (GBM-SC) have the capacity to initiate and sustain tumor growth and possess molecular characteristics similar to the parental tumor. GBM-SCs are known to be enriched in hypoxic niches and may contribute to therapeutic resistance. Therefore, to identify genetic determinants important for the proliferation and survival of GBM stem cells, an unbiased pooled shRNA screen of 10,000 genes was conducted under normoxic as well as hypoxic conditions. A number of essential genes were identified that are required for GBM-SC growth, under either or both oxygen conditions, in two different GBM-SC lines. Interestingly, only about a third of the essential genes were common to both cell lines. The oxygen environment significantly impacts the cellular genetic dependencies as 30% of the genes required under hypoxia were not required under normoxic conditions. In addition to identifying essential genes already implicated in GBM such as CDK4, KIF11, and RAN, the screen also identified new genes that have not been previously implicated in GBM stem cell biology. The importance of the serum and glucocorticoid-regulated kinase 1 (SGK1) for cellular survival was validated in multiple patient-derived GBM stem cell lines using shRNA, CRISPR, and pharmacologic inhibitors. However, SGK1 depletion and inhibition has little effect on traditional serum grown glioma lines and on differentiated GBM-SCs indicating its specific importance in GBM stem cell survival.Implications: This study identifies genes required for the growth and survival of GBM stem cells under both normoxic and hypoxic conditions and finds SGK1 as a novel potential drug target for GBM. Mol Cancer Res; 16(1); 103-14. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28993509      PMCID: PMC5752570          DOI: 10.1158/1541-7786.MCR-17-0146

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  52 in total

Review 1.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

2.  Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).

Authors:  A Brunet; J Park; H Tran; L S Hu; B A Hemmings; M E Greenberg
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

Authors:  E Robert McDonald; Antoine de Weck; Michael R Schlabach; Eric Billy; Konstantinos J Mavrakis; Gregory R Hoffman; Dhiren Belur; Deborah Castelletti; Elizabeth Frias; Kalyani Gampa; Javad Golji; Iris Kao; Li Li; Philippe Megel; Thomas A Perkins; Nadire Ramadan; David A Ruddy; Serena J Silver; Sosathya Sovath; Mark Stump; Odile Weber; Roland Widmer; Jianjun Yu; Kristine Yu; Yingzi Yue; Dorothee Abramowski; Elizabeth Ackley; Rosemary Barrett; Joel Berger; Julie L Bernard; Rebecca Billig; Saskia M Brachmann; Frank Buxton; Roger Caothien; Justina X Caushi; Franklin S Chung; Marta Cortés-Cros; Rosalie S deBeaumont; Clara Delaunay; Aurore Desplat; William Duong; Donald A Dwoske; Richard S Eldridge; Ali Farsidjani; Fei Feng; JiaJia Feng; Daisy Flemming; William Forrester; Giorgio G Galli; Zhenhai Gao; François Gauter; Veronica Gibaja; Kristy Haas; Marc Hattenberger; Tami Hood; Kristen E Hurov; Zainab Jagani; Mathias Jenal; Jennifer A Johnson; Michael D Jones; Avnish Kapoor; Joshua Korn; Jilin Liu; Qiumei Liu; Shumei Liu; Yue Liu; Alice T Loo; Kaitlin J Macchi; Typhaine Martin; Gregory McAllister; Amandine Meyer; Sandra Mollé; Raymond A Pagliarini; Tanushree Phadke; Brian Repko; Tanja Schouwey; Frances Shanahan; Qiong Shen; Christelle Stamm; Christine Stephan; Volker M Stucke; Ralph Tiedt; Malini Varadarajan; Kavitha Venkatesan; Alberto C Vitari; Marco Wallroth; Jan Weiler; Jing Zhang; Craig Mickanin; Vic E Myer; Jeffery A Porter; Albert Lai; Hans Bitter; Emma Lees; Nicholas Keen; Audrey Kauffmann; Frank Stegmeier; Francesco Hofmann; Tobias Schmelzle; William R Sellers
Journal:  Cell       Date:  2017-07-27       Impact factor: 41.582

4.  Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.

Authors:  Mariella Gruber Filbin; Sukriti K Dabral; Maria F Pazyra-Murphy; Shakti Ramkissoon; Andrew L Kung; Ekaterina Pak; Jarom Chung; Matthew A Theisen; Yanping Sun; Yoko Franchetti; Yu Sun; David S Shulman; Navid Redjal; Barbara Tabak; Rameen Beroukhim; Qi Wang; Jean Zhao; Marion Dorsch; Silvia Buonamici; Keith L Ligon; Joseph F Kelleher; Rosalind A Segal
Journal:  Nat Med       Date:  2013-09-29       Impact factor: 53.440

Review 5.  Hypoxia in astrocytic tumors and implications for therapy.

Authors:  David A Cavazos; Andrew J Brenner
Journal:  Neurobiol Dis       Date:  2015-06-19       Impact factor: 5.996

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  HYOU1/Orp150 expression in breast cancer.

Authors:  Alexander Stojadinovic; Jeffrey A Hooke; Craig D Shriver; Aviram Nissan; Albert J Kovatich; Tzu-Cheg Kao; Sathibalan Ponniah; George E Peoples; Maria Moroni
Journal:  Med Sci Monit       Date:  2007-11

8.  PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.

Authors:  Ganta Vijay Chaitanya; Alexander J Steven; Phanithi Prakash Babu
Journal:  Cell Commun Signal       Date:  2010-12-22       Impact factor: 5.712

9.  Measuring error rates in genomic perturbation screens: gold standards for human functional genomics.

Authors:  Traver Hart; Kevin R Brown; Fabrice Sircoulomb; Robert Rottapel; Jason Moffat
Journal:  Mol Syst Biol       Date:  2014-07-01       Impact factor: 11.429

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  11 in total

1.  A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.

Authors:  Claudia Silva-Evangelista; Emilie Barret; Virginie Ménez; Jane Merlevede; Thomas Kergrohen; Ambre Saccasyn; Estelle Oberlin; Stéphanie Puget; Kevin Beccaria; Jacques Grill; David Castel; Marie-Anne Debily
Journal:  Oncogene       Date:  2019-07-19       Impact factor: 9.867

2.  Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the SGK1 Gene Are Associated with Poorer Survival.

Authors:  Steven Lehrer; Peter H Rheinstein; Kenneth E Rosenzweig
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

3.  Development of Pyrazolo[3,4-d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme.

Authors:  Chiara Greco; Vincenzo Taresco; Amanda K Pearce; Catherine E Vasey; Stuart Smith; Ruman Rahman; Cameron Alexander; Robert J Cavanagh; Francesca Musumeci; Silvia Schenone
Journal:  ACS Med Chem Lett       Date:  2020-02-13       Impact factor: 4.345

4.  New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective.

Authors:  Simona Sestito; Massimiliano Runfola; Marco Tonelli; Grazia Chiellini; Simona Rapposelli
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

Review 5.  The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star.

Authors:  Ruizhe Zhu; Gang Yang; Zhe Cao; Kexin Shen; Lianfang Zheng; Jianchun Xiao; Lei You; Taiping Zhang
Journal:  Ther Adv Med Oncol       Date:  2020-07-15       Impact factor: 8.168

6.  Targeting NRF2, Regulator of Antioxidant System, to Sensitize Glioblastoma Neurosphere Cells to Radiation-Induced Oxidative Stress.

Authors:  Paulo R D V Godoy; Ali Pour Khavari; Marzia Rizzo; Elza T Sakamoto-Hojo; Siamak Haghdoost
Journal:  Oxid Med Cell Longev       Date:  2020-06-15       Impact factor: 6.543

7.  Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets.

Authors:  Dana Mitchell; Sreenivasulu Chintala; Kaleigh Fetcko; Mario Henriquez; Brij N Tewari; Atique Ahmed; R Timothy Bentley; Mahua Dey
Journal:  Front Oncol       Date:  2019-08-14       Impact factor: 6.244

8.  Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells.

Authors:  Lavinia-Lorena Pruteanu; Liliya Kopanitsa; Dezső Módos; Edgars Kletnieks; Elena Samarova; Andreas Bender; Leonardo Dario Gomez; David Stanley Bailey
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

Review 9.  Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy.

Authors:  Ilaria Guerriero; Gianni Monaco; Vincenzo Coppola; Arturo Orlacchio
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-22

10.  E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1.

Authors:  Peizhang Li; Huan Xu; Liu Yang; Ming Zhan; Yuanping Shi; Caoxu Zhang; Dajun Gao; Meng Gu; Yanbo Chen; Zhong Wang
Journal:  Cell Death Dis       Date:  2022-01-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.